Vestal Point Capital LP Sells 125,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Vestal Point Capital LP lessened its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 12.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 900,000 shares of the company’s stock after selling 125,000 shares during the quarter. Vestal Point Capital LP owned 2.46% of iTeos Therapeutics worth $6,912,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ITOS. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $42,000. Virtus ETF Advisers LLC boosted its holdings in shares of iTeos Therapeutics by 58.2% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after buying an additional 3,293 shares during the period. Forefront Analytics LLC acquired a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $85,000. Graham Capital Management L.P. acquired a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $85,000. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of iTeos Therapeutics in the fourth quarter valued at approximately $96,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Trading Down 2.0%

Shares of ITOS opened at $7.81 on Monday. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.70. The firm has a fifty day simple moving average of $6.61 and a 200 day simple moving average of $7.40. The stock has a market capitalization of $298.92 million, a price-to-earnings ratio of -2.48 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.14. As a group, research analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other iTeos Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the company’s stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the sale, the insider now directly owns 2,108,594 shares of the company’s stock, valued at approximately $16,995,267.64. This represents a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Ansbert Gadicke sold 1,031,931 shares of the company’s stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $8.06, for a total transaction of $8,317,363.86. Following the sale, the insider now directly owns 3,452,797 shares in the company, valued at $27,829,543.82. This trade represents a 23.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on ITOS. Wells Fargo & Company reiterated an “overweight” rating and issued a $13.00 price target (down previously from $16.00) on shares of iTeos Therapeutics in a report on Wednesday. JPMorgan Chase & Co. cut shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $15.00 to $8.00 in a report on Tuesday, May 13th. Leerink Partners reiterated a “market perform” rating and issued a $9.00 price target (down previously from $47.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Wedbush restated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, Leerink Partnrs cut shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 14th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, iTeos Therapeutics presently has a consensus rating of “Hold” and an average price target of $17.86.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.